Global Archives – Treatment Action Group

WHO Accelerated Platform for Novel Regimens

July 10, 2026
Adam Ortega

The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.

Community Research Advisors Group (CRAG) Consultant

July 6, 2026
Adam Ortega

Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.

Overcoming Barriers to Adopting the Four-Month Regimen: A Pathfinding Mission to Improve Access to Newer TB Treatments

June 23, 2026
Adam Ortega

A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access

Community and Civil Society Engagement Case Studies

June 16, 2026
Adam Ortega

The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.

Research Toward a Cure Trials

June 15, 2026
Jason Kirk

Ending HIV requires sustained research. TAG’s June 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.

Message from TAG Executive Director Mark Harrington: 45 Years Later, We Cannot Afford Inaction

June 4, 2026
Adam Ortega

Forty-five years ago the Centers for Disease Control and Prevention (CDC) published a brief report describing five cases of a rare pneumonia among young gay men in Los Angeles. The report occupied just a few paragraphs in the Morbidity and Mortality Weekly Report (MMWR). No one reading it could have known that it marked the beginning of one of the deadliest epidemics in modern history.

Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care

May 26, 2026
Jason Kirk

TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.

TAG and LAT CAB Welcome Indian Patent Office Decision That Could Expand Access to Hepatitis C Treatment

May 22, 2026
Jason Kirk

TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.

Financing Health Equity

May 15, 2026
Adam Ortega

The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…

Where Science Meets Justice: Before Most of Us Wake Up, TAG is Already Defending HIV Progress

May 5, 2026
Adam Ortega

Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.